Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial
Ge Tao(Honghu Hospital of Traditional Chinese Medicine), Peng Zhang(Tongji University), Wenxin He(Tongji University), Dongliang Bian(Tongji University), Minwei Bao(Tongji University), Hai Hu(China University of Petroleum, East China), Jie Huang(Tongji University), Xuefei Hu(Huazhong University of Science and Technology), Huansha Yu(Tongji University), Qiji Guo(Tongji University), Hongyi Zhang(Shanghai Pulmonary Hospital), Lele Zhang(Tongji University), Xinsheng Zhu(Ministry of Ecology and Environment), Yirui Zhou(Tongji University), Jincheng Su(Tongji University), Jie Yang(Tongji University), Yi Bao(Tongji University), Meixin Teng(Tongji University), Shiqi Hu(Columbia University Irving Medical Center), Suyu Wang(Tongji University), Yuming Zhu(Tongji University)
Cited by 0
Related Papers
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
|Genome Medicine|2023|369
MiR-7, Inhibited Indirectly by LincRNA HOTAIR, Directly Inhibits SETDB1 and Reverses the EMT of Breast Cancer Stem Cells by Downregulating the STAT3 Pathway
|Stem Cells|2014|366
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
|JAMA|2024|359
Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles
|Advanced Functional Materials|2017|297